Key Takeaways
- ATBS anchors the FY27 story: Management expects 15–20% volume growth in FY27 after a demand soft patch from October 2025, with Phase 2 expansion coming online by October.
- IBB hit by Iran war, now recovering: IBB volumes fell ~20% in FY26 on raw-material unavailability tied to the Iran conflict; the constraint is resolved and production is back on track.
- VOPL delayed, revenue pushed to H2: Process reengineering will take ~6 months, so meaningful revenue of ₹100–120 cr from the subsidiary is now expected only from Q3 FY27 onward.
- Long-term margin guide reset to 26–27%: Management framed this as a realistic band given expansions, new products and raw-material volatility, a step down from historical levels.
- What to watch next quarter: Whether the ATBS demand recovery holds through Q1 FY27, progress on the VOPL reengineering timeline, and any movement on the re-filed antioxidant ADD application.
ATBS: Demand, Capacity & the Growth Bet
- Demand softened from October 2025, interrupting the full-year target; management says recovery is now visible and expects 15–20% volume growth in FY27.
- Phase 1 expansion completed in FY26, taking utilization to ~80% (75% even after expansion), which management calls "pretty good."
- Phase 2 expansion will come into effect by October FY27, with fuller utilization flowing into FY28.
- Pricing remains stable under a formula-based mechanism, insulating the product from spot-market swings.
- Industry growth stays double-digit given ATBS's range of applications, including oil and gas; one or two smaller competing capacities have emerged but have not disrupted the trajectory.
- The 3-year bet: management expects 15% volume growth year-on-year for at least the next three years, which would absorb the expanded capacity.
Vinati Saraf Mutreja: "I would personally expect, say, 15% volume growth year-on-year, at least for the next 3 years and which would take care of our expansion."
Portfolio Headwinds & Recoveries
- IBB volume fell ~20% in FY26, driven by unavailability of key raw materials because of the Iran war; the constraint has now cleared and production and sales are back on track.
- Antioxidants grew revenue ~15% despite a challenging market, but the growth rate slowed to ~5% in FY26 as Chinese producers undercut aggressively; the company's anti-dumping-duty application was rejected along with 80–90% of industry applications and has been re-filed.
- Butyl phenol utilization sits at 70–75% with no room to expand capacity; any demand uptick will first be routed to captive consumption.
- Customized products grew 10% YoY on stronger customer demand.
- IB and HP-MTBE are expected to deliver double-digit growth in FY27.
Vinati Saraf Mutreja: "I believe in the period, about 80% or 90% applications of ADD were rejected and the Ministry of Commerce is in talks with the Ministry of Finance to give an explanation. Nevertheless, we have reapplied."
New Products & the Pipeline
- VOPL faces a 6-month delay: the plant encountered teething troubles with a new process; reengineering is underway with the main consultant, completion targeted by September, and production from October, pushing revenue contribution to Q3 FY27 onward.
- VOPL revenue expectation post-reengineering is ₹100–120 cr, with gross block asset turn expected to remain 1:1.
- MEHQ and Guaiacol revenue streams are expected to become active in FY27, contributing around ₹100 cr.
- 2–3 additional new products are expected in H2 FY27, with revenues materializing in FY28.
- Isoamylene derivatives dropped: the company is no longer pursuing tertiary amyl alcohol or PTAP.
- 4-MAP plans unchanged despite no knowledge of customer backward integration; the company may make something further from that product.
- Anisole will be produced in-house.
- Value-added capex of ~₹250 cr is earmarked for derivatives of MEHQ, derivatives of butyl phenols, and a couple of antioxidants, targeting food additives, fragrances and plastic additives; monomers and polymers may be explored but are not confirmed.
- Antioxidants plus butyl phenol revenue is expected to reach ₹800–900 cr over the next two years.
Vinati Saraf Mutreja: "Most of them, I think what's important, they are niche chemicals. We are targeting niche chemicals going forward."
Margins & the Long-Term Reset
- Long-term EBITDA margin guide set at 26–27%, framed as a realistic band that accounts for expansions, new product introductions and raw-material fluctuations.
- Sector cyclicality has intensified: cycles have shortened, customers overreact to demand-supply signals, panic-buy and then overstock, while raw-material and logistics price swings have grown steeper; management argues the company has managed these fluctuations well, maintained margins and passed on price changes.
- Growth will stay debt-free: the company plans to invest ₹250–300 cr annually for the next 3–5 years, funding organic expansion entirely from internal accruals.
Vinati Saraf Mutreja: "I think I've maintained an EBITDA margin of 26% to 27% because given expansions, new products, raw material fluctuations, I think that's a reasonably achievable EBITDA margin on a long-term basis."
Sector Dynamics & Competitive Landscape
- Cyclicality has shortened across the sector: customers panic and overstock, then destock, creating sharper demand swings than in the past; raw-material and logistics pricing fluctuations have also become steeper.
- Chinese competition is acute in antioxidants, with aggressive undercutting that has suppressed domestic volume growth despite 50% capacity utilization; the ADD reapplication, if successful, would still take 6–9 months for any outcome.
- ATBS competition remains limited to one or two smaller new capacities, and the company's formula-based pricing and integrated position have kept the franchise stable.
- The company does not supply ATBS directly to end-users in oil and gas; it sells to polymer manufacturers who then supply service companies like Halliburton and Schlumberger, so it has no direct visibility into end-demand shifts such as LNG extraction share moving to the U.S.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| ATBS volume growth | ~15–20% YoY | FY27 |
| ATBS volume growth | 15% YoY at least | Next 3 years |
| Company-level volume growth | ~15% | FY27 |
| ATBS Phase 2 expansion | Commissioning | October FY27 |
| VOPL production restart | Post-reengineering completion | October FY27 (revenue from Q3) |
| VOPL revenue | ₹100–120 cr | Post-reengineering, from FY27 Q3 onward |
| MEHQ / Guaiacol revenue | ~₹100 cr | FY27 |
| New products (2–3) | Launch | H2 FY27, revenues in FY28 |
| Antioxidants + butyl phenol revenue | ₹800–900 cr | Next 2 years |
| Annual capex | ₹250–300 cr | Next 3–5 years |
| FY27 capex | ₹200–250 cr | FY27 |
| Value-added products capex | ~₹250 cr | Ongoing |
| Long-term EBITDA margin | 26–27% | Long-term basis |
| ADD on antioxidants | Decision timeline | 6–9 months from reapplication, if successful |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Standalone net income (incl. other income) | ₹631 cr, up 17% QoQ from ₹538 cr |
| Standalone EBITDA | ₹203 cr, up 20% QoQ from ₹169 cr |
| Standalone PAT | ₹137 cr, up 27% QoQ from ₹108 cr |
| Consolidated net income (incl. other income) | ₹624 cr, up 16% QoQ from ₹540 cr |
| Consolidated EBITDA | ₹191 cr, up 15% QoQ from ₹165 cr |
| Consolidated PAT | ₹123 cr, up 23% QoQ from ₹101 cr |
| FY26 standalone net income (incl. other income) | ₹2,281 cr, stable vs FY25 |
| FY26 standalone EBITDA | ₹741 cr, up 17% from ₹630 cr in FY25 |
| FY26 standalone PAT | ₹488 cr, up 18% from ₹415 cr in FY25 |
| FY26 consolidated net income (incl. other income) | ₹2,280 cr, stable vs FY25 |
| FY26 consolidated EBITDA | ₹707 cr, up 13% from ₹625 cr in FY25 |
| FY26 consolidated PAT | ₹444 cr, up 9% from ₹405 cr in FY25 |
| ATBS volume growth outlook (FY27) | 15% to 20%, recovery expected after demand softened from October 2025 |
| Company-level volume growth target (FY27) | ~15% |
| ATBS capacity utilization | ~80%, 75% even after expansion |
| Butyl phenol capacity utilization | 70% to 75% |
| IBB volume decline (FY26 vs FY25) | ~20%, partly due to raw material unavailability from Iran war |
| Customized products segment growth (FY26) | 10% YoY |
| Antioxidants revenue growth (FY26) | 15%, despite challenging market environment |
| FY26 capex incurred | ~₹270 cr, including VOPL investments |
| FY27 capex projection | ₹200 cr to ₹250 cr, of which ₹40-50 cr in VOPL, ₹200 cr in main holding company |
| Treasury as of March 31, 2026 | ~₹190 cr |
| Dividend recommended for FY26 | ₹8.50 per equity share of face value ₹1 |
| VOPL revenue in FY26 | ~₹10 cr, hardly any sale |
| VOPL expected revenue (FY27) | ₹100 cr to ₹120 cr, after reengineering, from Q3 onwards |
| ATBS capacity (lower molecular weight) | 50,000 tonnes; 40,000 tonnes for higher purity; each phase 10,000 tonnes |
| ATBS Phase 1 and Phase 2 combined capex | ₹250 cr to ₹300 cr |
| CWIP at year-end | ~₹210 cr; ₹60-70 cr yet to be capitalized under VOPL, ₹120-125 cr in VOPL to be capitalized in FY27 |
| Antioxidants plus butyl phenol revenue target | ₹800 cr to ₹900 cr, to be achieved in next 2 years |
| Long-term EBITDA margin outlook | 26% to 27% |
| Annual capex expectation (next 3-5 years) | ₹250 cr to ₹300 cr |